This might be due to lack of tumour antigen recognition by T cells, the loss of beta-2-microglobulin and HLA (antigen-presenting machinery components), as well as tumour cell–induced or myeloid cell–induced inactivation of T-cell signalling, and activation or a loss of sensitivity to T effector molecules by the cancer cells. Here, B2M is linked to neoplasm.